Veeva Systems
VEEV
$197.41
+1.04%
Veeva Systems is the global leading supplier of cloud-based software solutions for the life sciences industry, offering customer relationship management (CRM) and content management (Vault) platforms that address operating and regulatory requirements for pharmaceutical and biotechnology companies. As a dominant niche player, Veeva has carved out a defensible position by replacing legacy enterprise resource planning systems with purpose-built, compliant cloud tools. The current investor narrative centers on a sharp 35% decline from 52-week highs, which has sparked debate about whether the stock is a value trap or a buying opportunity given its entrenched market position and clear path to doubling revenue by 2030, as highlighted by recent bullish commentary from The Motley Fool.…
VEEV
Veeva Systems
$197.41
Related headlines
VEEV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veeva Systems's 12-month outlook, with a consensus price target around $244.59 and implied upside of +23.9% versus the current price.
Average Target
$244.59
0 analysts
Implied Upside
+23.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $350
Analyst target range
Veeva is covered by 27 analysts, with a consensus recommendation of 'Buy' (mean rating 1.93 on a 1-5 scale where 1 is Strong Buy). The average price target is $244.59, implying 25.2% upside from the current price of $195.38. The distribution shows 10 recent ratings from June 4, 2026, including 6 Buy/Outperform, 2 Hold/Neutral, and 2 In Line, indicating a bullish tilt. The target range spans from $165.00 (low) to $350.00 (high), a wide spread of $185 that signals high uncertainty. The low target of $165 implies a 15.5% downside, potentially pricing in margin compression or competitive loss, while the high target of $350 assumes multiple expansion and accelerating growth. The wide range suggests low conviction among analysts, consistent with the stock's recent volatility and binary outcome scenarios.
Bulls vs Bears: VEEV Investment Factors
Veeva Systems presents a classic growth-at-a-reasonable-price debate. On the bull side, its dominant niche in life sciences cloud, high margins, debt-free balance sheet, and 25% analyst upside argue for a buying opportunity after a 35% decline. On the bear side, decelerating revenue growth, a high trailing P/E of 36.7x, and persistent underperformance versus the market suggest the stock may still be overvalued. The single most important tension is whether revenue growth can stabilize or reaccelerate above 20%—if it does, the forward P/E of 19.5x will look cheap; if it falls below 15%, the stock could test the $165 low target. Currently, the evidence slightly favors the bull case given the strong competitive position and reasonable forward multiple, but the wide analyst range signals high uncertainty.
Bullish
- Dominant Niche with High Switching Costs: Veeva is the leading cloud provider for life sciences, with CRM and Vault platforms deeply integrated into pharma workflows. Its 75.5% gross margin and 28.7% operating margin reflect pricing power and customer stickiness, making displacement difficult.
- Strong Revenue Growth with Clear Path to Double: Revenue grew 16.3% YoY to $882.9M in Q1 FY2027, and analysts estimate FY2027 revenue of $5.69B. The Motley Fool highlights a clear path to doubling revenue by 2030, supported by expanding Vault adoption and international expansion.
- Analyst Consensus Buy with 25% Upside: 27 analysts rate VEEV a Buy (mean 1.93), with an average price target of $244.59, implying 25.2% upside from $195.38. The high target of $350 suggests potential for 79% upside if growth reaccelerates.
- Excellent Financial Health with Zero Debt: Veeva has a debt-to-equity ratio of 0.013 (virtually debt-free) and a current ratio of 4.89, indicating strong liquidity. Free cash flow TTM is $1.64B, providing ample resources for investment and buybacks.
Bearish
- Decelerating Revenue Growth Trend: Revenue growth slowed from 20.1% YoY in Q1 FY2026 to 16.3% in Q1 FY2027. Sequential deceleration raises concerns about market saturation and peak growth rates, which could compress multiples further.
- High Trailing P/E Signals Overvaluation Risk: The trailing P/E of 36.7x is elevated relative to the healthcare IT sector average (~25-30x). If growth decelerates more than expected, multiple compression could drive the stock to the analyst low target of $165 (15.5% downside).
- Sustained Underperformance vs. Market: VEEV has declined 29.3% over the past year versus the S&P 500's gain of 18.4%, with relative strength of -47.7%. This persistent weakness may indicate structural headwinds or loss of investor confidence.
- Wide Analyst Target Range Indicates Uncertainty: Analyst targets range from $165 to $350, a spread of $185 (95% of current price). This wide dispersion suggests low conviction and binary outcomes, making the stock risky for conservative investors.
VEEV Technical Analysis
Veeva is in a sustained downtrend, with the stock down 29.3% over the past year compared to the S&P 500's gain of 18.4%. The current price of $195.38 sits at 28.5% of its 52-week range (low $148.05, high $310.50), indicating the stock is trading near the lower end of its annual range. This positioning near the lows suggests either a potential value opportunity or a falling knife, depending on whether fundamentals support a recovery. The 1-year relative strength of -47.7% versus the S&P 500 underscores persistent underperformance.
Beta
0.94
0.94x market volatility
Max Drawdown
-50.5%
Largest decline past year
52-Week Range
$148-$311
Price range past year
Annual Return
-30.1%
Cumulative gain past year
| Period | VEEV Return | S&P 500 |
|---|---|---|
| 1m | +28.8% | -0.6% |
| 3m | +17.7% | +5.4% |
| 6m | -10.2% | +8.3% |
| 1y | -30.1% | +18.3% |
| ytd | -10.1% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VEEV Fundamental Analysis
Revenue growth remains robust but is decelerating. In the most recent quarter (Q1 FY2027, ended April 30, 2026), revenue reached $882.9 million, up 16.3% year-over-year, compared to 20.1% growth in the prior-year quarter. The sequential trend shows growth slowing from 20.1% (Q1 FY2026) to 16.3% (Q1 FY2027), though still healthy. Subscription services revenue of $337.9 million in the Commercial Cloud segment continues to be the primary growth driver, while Professional Services contributed $57.6 million. The deceleration is typical for a maturing platform but raises questions about peak growth rates.
Quarterly Revenue
$882948000.0B
2026-04
Revenue YoY Growth
+16.3%
YoY Comparison
Gross Margin
74.7%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VEEV Overvalued?
Since net income is positive ($260.9 million in Q1 FY2027), the primary valuation metric is the P/E ratio. The trailing P/E stands at 36.7x, while the forward P/E is 19.5x, implying the market expects significant earnings growth over the next year. The gap between trailing and forward P/E suggests aggressive growth expectations baked into the stock. Compared to the healthcare information services industry, Veeva's trailing P/E of 36.7x is at a premium to the sector average (not provided, but typically ~25-30x for SaaS peers), reflecting its dominant niche and high margins.
PE
36.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~97x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Veeva's primary financial risk is revenue deceleration, with YoY growth falling from 20.1% to 16.3% in the latest quarter. While the company has no debt and strong liquidity (current ratio 4.89), its high operating margin of 28.7% leaves limited room for margin expansion if growth slows further. The net income margin of 29.6% is healthy, but any compression could pressure the trailing P/E of 36.7x, which already prices in significant earnings growth. Free cash flow of $1.64B TTM provides a cushion, but the stock's valuation remains dependent on sustained double-digit growth.
Market & Competitive Risks: Veeva trades at a premium to the healthcare IT sector (trailing P/E 36.7x vs. ~25-30x), making it vulnerable to multiple compression if growth disappoints. The stock's beta of 0.94 suggests moderate market correlation, but its 1-year relative strength of -47.7% versus the S&P 500 indicates it has been out of favor. Competitive risks include potential disruption from larger tech firms (e.g., Salesforce, Microsoft) entering the life sciences niche, though Veeva's deep domain expertise and regulatory compliance features create high switching costs. Geopolitical headlines (e.g., Iran tensions) could also weigh on growth stocks.
Worst-Case Scenario: If revenue growth decelerates below 10% due to market saturation or competitive losses, the forward P/E could contract to 15x, implying a stock price of ~$130 (based on FY2027 EPS estimates of $14.49). This represents a 33% decline from the current $195.38 and would approach the 52-week low of $148.05. The historical max drawdown of -50.55% suggests that in a severe downturn, the stock could fall to ~$97, though this would require a fundamental crisis such as a major customer loss or regulatory change.